Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral
anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) …

The relationship between apolipoprotein B (APOB) and atrial fibrillation (AF) is less well-
known. We aimed to investigate the association between APOB and AF by gender. We …

Aims: To assess the impact of anticoagulant treatment, on risk for stroke and all-cause
mortality of patients with atrial fibrillation, using real world data. Methods: Patients with …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Purpose Database heterogeneity can impact effect estimates. Harmonisation provided by
common protocols and common data models (CDMs) can increase the validity of …

Background Suboptimal low dosages of non-vitamin K antagonist oral anticoagulants
(NOACs) are often inappropriately used due to a fear of bleeding, particularly among elderly …

Background The use of anticoagulants is an established strategy to prevent stroke,
embolism, and cardiovascular mortality in patients with atrial fibrillation (AF), but its role in …

The objective is to assess the impact of anticoagulant treatment in non-valvular atrial
fibrillation (AF) and different categories of renal dysfunction in real world. Electronic Health …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …